Autopsy report · NCT07061080

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

“AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its support for the study, which means the clinical trial will be terminated early.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 9 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Grupo Espanol de Tumores Neuroendocrinos

Sponsor type

University, hospital or other

Conditions

Advanced Neuroendocrine Carcinomas of The Digestive System; Advanced Neuroendocrine Carcinomas Unknown Primary Origin

Interventions

Tarlatamab; standard of care second-line chemotherapy (FOLFIRI)

Participants

1

Sites

19

Countries

France, Spain

Trials that died the same way

• Safety & Tolerability of Cinacalcet in Pediatric Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism
  “Amgen decided to terminate the study early to be able to meet US regulatory timelines fo filing. Subjects in treatment were rolled over to the 20140159 study.” (76% match in meaning)
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
  “Amgen decided to discontinue study because of a business decision and not because of safety reasons” (69% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (62% match in meaning)
• Medication Use Among American Indians Adults
  “The study has not been stopped. The study does not qualify as a clinical trial so it was withdrawn from clinicaltrials.gov.” (61% match in meaning)
• Antibiotics and Tissue Expanders in Breast Reconstruction
  “The study was withdrawn prior to IRB approval.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.